Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenues	$ 0	$ 0
Costs and expenses:
Research and development	20,395,136	11,997,272
General and administrative	10,008,173	8,148,803
Total operating expenses	30,403,309	20,146,075
Loss from operations	(30,403,309)	(20,146,075)
Other income (expense):
Interest expense	(8,859)	(31,229)
Change in fair value of derivative instruments-warrants and contingent consideration	(2,310,000)	(146,050)
Loss before income taxes	(32,722,168)	(20,323,354)
Income tax benefit (expense)	0	(30,584)
Net loss	(32,722,168)	(20,353,938)
Deemed dividend (see Note 5)	0	(5,287)
Net loss attributable to common stockholders, basic	(32,722,168)	(20,359,225)
Net loss attributable to common stockholders, diluted	$ (32,722,168)	$ (20,359,225)
Weighted average common shares outstanding:
Basic (in shares)	70,291,535	9,677,832
Diluted (in shares)	70,291,535	9,677,832
Net loss per common share: (see Note 11)
Basic (in dollars per share)	$ (0.47)	$ (2.10)
Diluted (in dollars per share)	$ (0.47)	$ (2.10)